Home › Ependymoma › NCT03750513

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Pilot Trial of LET Optimized IMPT for Pediatric Patients With Ependymoma

Who can join

Up to age 22 · All sexes

Inclusion Criteria:

* Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
* Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
* Patient may not receive chemotherapy concurrent with radiation
* Signed informed consent by patient and/or parents or legal guardian
* Lansky performance status score of 50 -100

Exclusion Criteria:

* Patients with previous radiation therapy to the brain
* Ependymoma of the spine
* Disseminated ependymoma requiring craniospinal radiation therapy
* Pregnancy
* Inability to undergo MR imaging
* Inability to receive gadolinium-based contrast agent

About the study

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

What is being tested

• Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy (radiation)
• Quality-of-Life Assessment (other)
• Questionnaire Administration (other)

Sponsor: M.D. Anderson Cancer Center · Participants: 48 · Started: Apr 1, 2019

Contact the study team

• David Grosshans · Phone: 713-563-2300

Official record on ClinicalTrials.gov — NCT03750513

Locations in the U.S.

Conditions

• Ependymoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.